We investigated anticholinergic medicines use among older adults initiating dementia medicines.
| INTRODUCTION
Nearly 50 million people worldwide are currently living with dementia. 1, 2 Cholinesterase inhibitors and memantine (dementia medicines)
are the approved pharmacological mainstays and part of the standard care for managing the symptoms of dementia but they do not reverse or stop its progression. 3, 4 Dementia medicines have the potential to cause agitation, insomnia and incontinence 5 and these unwanted effects might lead to initiation or increased use of anticholinergic medicines. [6] [7] [8] [9] Additionally, older adults with dementia are commonly prescribed medicines with anticholinergic properties to treat comorbidities such as depression, and anxiety and this further complicates therapy with dementia medicines. 10 Anticholinergic medicines may cause cognitive impairment, confusion, loss of concentration and delirium, which are exaggerated in older adults with dementia. 5, [11] [12] [13] Moreover, use of anticholinergic medicines may reduce the therapeutic effects of dementia medicines.
A recent population-based study investigating the effect of high anticholinergic burden after starting cholinesterase inhibitors found that concomitantly use of anticholinergic medicines had a negative impacted on the treatment response to cholinesterase inhibitors, leading to treatment modification, delirium and mortality. 14 In an attempt to reduce variation in the management of dementia and to improve quality of care, best practice guidelines including those of the National Institute for Health and Care Excellence and American
Psychiatric Association now recommend medicine reviews at the time of diagnosis to reduced irrational medicine use in patients with dementia. [15] [16] [17] [18] [19] These reviews also provide an opportunity to identify and rule out any reversible cause of confusion such as adverse effects of other medicines or untreated comorbidities. 20 Recommendations on improving clinical outcomes have been updated; however, decisions on reducing potentially inappropriate combinations of medicines, such as concomitant use of dementia and anticholinergic medicines are challenging due to lack of clarity in guidelines for managing comorbidities in patients with dementia. 16 In Australia, few studies have investigated the use of anticholinergic medicines at the time of initiating dementia therapy. 21 
| Medicines of interest
We included 3 cholinesterase inhibitors subsidised under PBS for the management of cognitive impairment in patients with mild to moderately severe Alzheimer disease: donepezil (ATC code N06DA02),
What is already known about this subject
• Adverse effects of anticholinergic medicines are exaggerated in older adults with dementia and may worsen symptoms of dementia.
• Recent campaigns have encouraged clinicians to put more focus on appropriate use of medicines for older adults.
What this study adds
• Despite their antagonistic pharmacological effects, current real-world evidence shows that 1/3 of patients initiating dementia medicines were exposed to anticholinergic medicines up to 180 days before or after.
• There is a myriad of guidelines on managing symptoms of dementia; however, deprescribing medicines with questionable benefit among patients with dementia are complicated by conflicting recommendations, especially approaches to manage co-existing morbidities.
rivastigmine (ATC code N06DA03) and galantamine (ATC code N06DA04). We also included memantine (ATC code N06DX01), a N-methyl-d-aspartate receptor inhibitor which is subsidised for patients with moderately severe to severe Alzheimer disease.
There is a wide range of medicines with anticholinergic effects. We limited the selection of these medicines based on a previously published list by Kalisch Ellett and colleagues 13 who used medicines listed on the anticholinergic risk scale and the anticholinergic drug scale to
show associations between anticholinergic medicine use and risk of hospitalisation with confusion or dementia. 13 Table S1 lists these medicines, their ATC codes, therapeutic use and medicine class.
| Study cohort and medicines exposure
Our study comprised all adults in the PBS 10% sample, aged ≥60 years, who were initiated cholinesterase inhibitors or memantine during the study period and continued dispensings for at least 180 days. We defined initiation of therapy to be the first dementia medicines dispensing after a period of at least 180 days, during which no dispensing of any dementia medicines had occurred.
We assumed that the person had remained on therapy for at least 180 days, if they had ≥5 dispensings of their dementia medicines within 180 days after the date of initiation. We required ≥5 dispensings for donepezil, galantamine and memantine 20-mg tablets as they are available in 28-day pack sizes for once daily dosing and oral formulations of rivastigmine are available in 56-capsule packs for twice daily dosing. For memantine 10-mg tablets, we required only ≥3 dispensings, as the available pack size is 56-tablet packs and can be used as once-daily dosing. 25 We defined exposure to anticholinergic medicines before dementia therapy as any dispensing of an anticholinergic medicine 1-180 days prior to initiating dementia medicines. We defined exposure to anticholinergic medicines after initiation of dementia therapy as any dispensing of an anticholinergic within 180 days after initiating dementia medicines (i.e. including same day dispensings of an anticholinergic medicine with cholinesterase inhibitors or memantine). Figure S1 demonstrates the selection of the study cohort and their exposure to medicines with anticholinergic effects from the period 180 days before and until 180 days after.
| Data analysis
We described the patient characteristics, their exposure to anticholinergic medicines and calculated the number and proportion of patients and 89 years and 69% initiated donepezil as their dementia treatment (Table 1) .
One-third of the study cohort (1439/4393) was exposed to least 1 anticholinergic medicine in the 180 days before or after initiating dementia medicines. Of those exposed, nearly 2/3 (59%) were dispensed antipsychotic medicines. Risperidone was the most common anticholinergic medicine dispensed (29% of those exposed), followed by prochlorperazine (18%), amitriptyline (16%), quetiapine (14%) and oxybutynin (13%).
The proportion of patients exposed to anticholinergic medicines in each 30-day period ranged from 9.7 to 10.7% during the 180 days before initiating dementia medicines and from 13.0 to 13.5% after initiating dementia medicines ( Figure 1 ).
We observed a 2.5% absolute increase in the number of patients dispensed anticholinergic medicines after initiating dementia medicines with the largest increase in the concomitant dispensing of antipsychotics (10.1%). We found that more patients were dispensed risperidone and quetiapine after initiating dementia medicines (7.3 and 2.3% respectively) than during the 180 days before such therapy (Table 2 ).
Among patients exposed to an anticholinergic medicine, approximately 1/3 (416/1439) commenced treatment after initiating dementia medicines, while nearly half (659/1439) had the same anticholinergic medicine dispensed before and after initiating dementia medicines. Risperidone was most commonly dispensed (37.5%)
among those who commenced anticholinergic medicines after initiation of dementia therapy (Table 3) , and among those with exposure to same anticholinergic medicines (22.8%) before and after. (Table S2 ).
Among patients who were dispensed anticholinergic medicines after initiating dementia medicines (with or without prior exposure),
we found that nearly half (537/1133) had their anticholinergic medicines prescribed by a prescriber other than the one who initiated dementia therapy.
| DISCUSSION
Dementia is a progressive disease and medicines for dementia might slow the cognitive decline. Our study provides insight into recent real-world use of medicines for dementia and the prescribing of medicines with anticholinergic effects in this population. Current recommendations encourage a medicine review at the time of dementia diagnosis and thereafter to reduce potentially inappropriate medicine
use, yet we found that anticholinergic medicines were commonly dispensed to our cohort.
The results of our study mirror the findings of previous studies conducted almost a decade ago using PBS dispensing data, 21, 22 suggesting that there has been little change in prescribing practices among patients dispensed dementia medicines. These results occur against a backdrop of increasing emphasis on the importance of evidence-based practice and calls for improved prescribing in this vulnerable population. Our findings are also comparable to international studies. In a very recent systematic review, Hukins and colleagues identified anticholinergic medicines as among the most commonly prescribed potentially inappropriate medicines among patients with dementia, with rates of prescriptions ranging from 6 to 46%. 27 There is a myriad of guidelines on managing symptoms of dementia; however, they often lack depth, consistency and/or consensus and the overall recommendations on managing comorbidities are generally weak and/or based upon insufficient evidence. 28 This leads to increased challenges for clinicians with ever-extensive clinical responsibilities and makes it difficult to determine what approach to take. For instance, concurrent use of anticholinergic medicines is not recommended with cholinesterase inhibitors; however, the primary pharmacological management for behavioural and psychological disturbances in dementia are antipsychotics such as risperidone. 15, 18, [28] [29] [30] [31] [32] In our study, the antipsychotic risperidone was the most commonly dispensed medicine with anticholinergic effects both before and after initiating dementia medicines. Under PBS restrictions, risperidone formulations are only eligible for government subsidy for managing behavioural and psychological symptoms of dementia; thus accounting for the substantial number of dispensings captured in our data. 33 The Other anticholinergic medicines commonly co-dispensed among our study cohort, such as prochlorperazine, loperamide, oxybutynin and amitriptyline, may have been used to manage the adverse effects of dementia medicines, such as nausea, diarrhoea, agitation, insomnia and incontinence. 5 This suggests that the initiation of dementia medicines may have led to a prescribing cascade 7 and use of medicines with the potential to worse cognition, among other adverse effects.
This might be most obvious with the prescription of the anticholinergic medicine oxybutynin to manage urinary symptoms that results from therapy with dementia medicines.
11
Patients with dementia experience more comorbidities, may receive a higher number of medicines and visit multiple prescribers in comparison to their cognitively intact counterparts, which leads to fragmentation of care. 27, 38, 39 In our study, we found that nearly half of the cohort who were co-prescribed anticholinergic and dementia medicines visited multiple prescribers. This may have contributed to polypharmacy and irrational combinations of pro-cholinergic and anticholinergic medicines. For example, drug-interaction software can only work if both medicines are recorded in the same system, and prescribers would be familiar with the medicines they choose to prescribe but might be ignorant of others. (%) presented are proportions of all patients in the cohort dispensed an anticholinergic medicine (n = 1439).
This table contains patients who may have received a dispensing of >1 type of anticholinergic medicines during the study period.
a Table S1 outlines the anticholinergic medicine classes. (%) presented are proportions of all patients dispensed anticholinergic medicines for the first time after initiating dementia medicines (n = 416).
This table contains patients who may have received a dispensing of >1 type of anticholinergic medicine during the study period.
SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article. 
